Plain language summary of the development of tepotinib: a treatment for a subtype of non-small cell lung cancer called exon 14 skipping.

What Is This Summary About?: This plain language summary provides an overview of two of the main clinical studies that led to tepotinib's approval, the phase I first-in-human study and the phase II VISION study.

What Is Tepotinib?: Tepotinib is a targeted anti-cancer treatment taken orally (by mouth). It is available in many countries for people with advanced or metastatic non-small cell lung cancer (NSCLC), where the tumor contains a genetic mutation (alteration) called ' exon 14 skipping'.